price
BB
NASDAQ · BBOT
BridgeBio Oncology Therapeutics Inc.
Healthcare · Biotechnology
$4.88
Down-$0.17 (-3.37%)
Updated Sep 16, 2026, 9:01 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.03B
- P/E ratio
- -2.62
- Dividend yield
- 0.00%
- 52-week range
- $4.85 – $14.87
- Volume
- 629.2K
- Avg. volume
- 237.22K
Price performance
BBOT price history
1M range · 20 trading sessions · Daily adjusted prices
BBOT closed at $4.88 after 20 trading sessions, down 45.47% for the selected period.
- Last close
- $4.88
- Period change
- -45.47%
- Period low
- $4.88
- Period high
- $9.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.01 | $5.015 | $4.72 | $4.88 | 629.2K |
| Sep 14, 2026 | $4.91 | $5.18 | $4.85 | $5.05 | 956.1K |
| Sep 11, 2026 | $5.53 | $5.616 | $4.90 | $4.95 | 1.63M |
| Sep 10, 2026 | $6.785 | $6.785 | $5.48 | $5.52 | 2.79M |
| Sep 9, 2026 | $8.86 | $8.86 | $6.295 | $6.755 | 1.5M |
| Sep 8, 2026 | $8.88 | $9.05 | $8.775 | $8.86 | 154.11K |
| Sep 4, 2026 | $8.80 | $9.06 | $8.65 | $8.98 | 117.62K |
| Sep 3, 2026 | $8.93 | $9.0411 | $8.66 | $8.90 | 139.21K |
| Sep 2, 2026 | $8.81 | $9.185 | $8.73 | $8.89 | 238.88K |
| Sep 1, 2026 | $8.70 | $8.90 | $8.535 | $8.82 | 146.13K |
| Aug 31, 2026 | $8.72 | $9.195 | $8.4101 | $8.80 | 476.04K |
| Aug 28, 2026 | $9.16 | $9.16 | $8.69 | $8.74 | 195.04K |
| Aug 27, 2026 | $9.19 | $9.315 | $9.06 | $9.18 | 385.27K |
| Aug 26, 2026 | $9.36 | $9.47 | $9.04 | $9.26 | 247.15K |
| Aug 25, 2026 | $9.24 | $9.4725 | $9.18 | $9.37 | 197.97K |
| Aug 24, 2026 | $9.10 | $9.3575 | $8.80 | $9.14 | 338.52K |
| Aug 21, 2026 | $9.19 | $9.4351 | $9.03 | $9.08 | 171.57K |
| Aug 20, 2026 | $9.55 | $9.78 | $9.08 | $9.08 | 203.26K |
| Aug 19, 2026 | $9.16 | $9.72 | $9.14 | $9.60 | 414.32K |
| Aug 18, 2026 | $9.02 | $9.125 | $8.82 | $8.95 | 446.87K |
Latest BBOT news
The latest Smart Investors Daily articles mentioning BBOT.
Stock researchCompany · Overview
BBOT research
Overview
Company profile and research snapshot.
Company profile
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 10, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Stifel | Buy | — |
| Sep 9, 2026 | Raymond James | Outperform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.